These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 20308673)
21. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119 [TBL] [Abstract][Full Text] [Related]
22. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
23. Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. Bandrés E; Malumbres R; Escalada A; Cubedo E; González I; Honorato B; Zarate R; García-Foncillas J; de Alava E J Pediatr Hematol Oncol; 2005 Oct; 27(10):537-42. PubMed ID: 16217257 [TBL] [Abstract][Full Text] [Related]
24. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells. Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505 [TBL] [Abstract][Full Text] [Related]
25. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? Zoubek A; Dockhorn-Dworniczak B; Delattre O; Christiansen H; Niggli F; Gatterer-Menz I; Smith TL; Jürgens H; Gadner H; Kovar H J Clin Oncol; 1996 Apr; 14(4):1245-51. PubMed ID: 8648380 [TBL] [Abstract][Full Text] [Related]
26. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598 [TBL] [Abstract][Full Text] [Related]
27. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264 [TBL] [Abstract][Full Text] [Related]
28. Molecular detection of EWS-Ets fusion transcripts and their clinicopathologic significance in Ewing's sarcoma/peripheral primitive neuroectodermal tumor. Wang H; Zheng J; Wang YP; Yang Y; You JF Chin Med J (Engl); 2005 Aug; 118(16):1323-9. PubMed ID: 16157025 [TBL] [Abstract][Full Text] [Related]
29. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Hu-Lieskovan S; Zhang J; Wu L; Shimada H; Schofield DE; Triche TJ Cancer Res; 2005 Jun; 65(11):4633-44. PubMed ID: 15930281 [TBL] [Abstract][Full Text] [Related]
30. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. Lai R; Navid F; Rodriguez-Galindo C; Liu T; Fuller CE; Ganti R; Dien J; Dalton J; Billups C; Khoury JD J Pathol; 2006 Apr; 208(5):624-32. PubMed ID: 16463269 [TBL] [Abstract][Full Text] [Related]
31. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Amann G; Zoubek A; Salzer-Kuntschik M; Windhager R; Kovar H Hum Pathol; 1999 Sep; 30(9):1058-64. PubMed ID: 10492040 [TBL] [Abstract][Full Text] [Related]
32. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056 [TBL] [Abstract][Full Text] [Related]
33. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor. Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587 [TBL] [Abstract][Full Text] [Related]
34. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma. Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833 [TBL] [Abstract][Full Text] [Related]
35. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423 [TBL] [Abstract][Full Text] [Related]
36. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846 [TBL] [Abstract][Full Text] [Related]
38. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle. Asami S; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T Biol Pharm Bull; 2008 Mar; 31(3):391-4. PubMed ID: 18310898 [TBL] [Abstract][Full Text] [Related]